We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...

"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...

On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...

European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over Novo ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

Ozempic-curious people are taking a novel approach to using the blockbuster weight loss drug — and some doctors are even ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...

In the U.K., a pharma-run watchdog has been issuing fines and levying suspensions. Could this help build public trust?

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...